Biomark Capital is an institutional investor (Conventional VCs) founded in 2013 and headquartered in San Francisco, United States. Venture capital firm investing in life science companies to improve healthcare. They provide venture funding and assistance to early, mid, and late-stage life science companies. The firm targets companies with novel approaches to diagnostics, therapeutics, medical devices, and digital health, aiming to change healthcare innovation. They partner with entrepreneurs to develop groundbreaking platform technologies into successful ventures. Their investment strategy focuses on innovation across the healthcare spectrum, including therapeutics, medical devices, molecular diagnostics, healthcare delivery, and information technology. They seek highly disruptive innovations addressing large clinical unmet medical needs, with strong management teams and established proof-of-concept. The firm aims to impact global healthcare by investing capital and expertise in promising life science companies, generating returns for investors.

Stage

early-stage, mid-stage, late-stage, early-stage, mid-stage, late-stage

Check size

$10M-$50M

HQ

San Francisco, United States

Founded

2013

Website

https://www.biomarkcapital.com

LinkedIn

https://linkedin.com/company/orvel-ventures

What they look for

primarily United States and Taiwan; preference for more mature startups (average age 16 years at investment)

Preparing to pitch Biomark Capital?

CrackTheDeck analyzes your pitch deck before the meeting — structure, narrative, investor fit.